Top

BMC Cancer

Published in:

Open Access 01-12-2023 | Kidney Cancer | Research

Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study

Authors: Haohao Lu, MD, Qing Ye, MD, Chuansheng Zheng, MD,PhD, Li Fan, MD,PhD, Xiangwen Xia, MD,PhD

Published in: BMC Cancer | Issue 1/2023

Abstract

Background

Since renal cell carcinoma(RCC) is insensitive to conventional chemoradiotherapy, molecularly targeted drugs are commonly used treatments for unresectable advanced RCC. The aim of this study was to explore the efficacy and safety of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced RCC.

Methods

This study included 98 patients with unresectable advanced RCC who were treated in Union Hospital from January 2015 to December 2018, and they met the criteria. They were divided into two groups: TACE + Sunitinib group (N = 47) and Sunitinib group (N = 51). We conducted a retrospective study to analyze the efficacy and safety of the two groups of patients.

Results

(1)TACE + Sunitinib group: 4 patients (8.5%) achieved CR, 27 patients (57.5%) achieved PR, 9 patients (19.1%) achieved SD, and 7 patients (14.9%) achieved PD. Sunitinib group, 0 patients (0%) achieved CR, 20 patients (39.2%) achieved PR, 14 patients (27.5%) achieved SD, and 17 patients (33.3%) achieved PD. (P = 0.017) (2)ORR: TACE + sunitinib group, 66.0%; sunitinib group, 39.2%. (P = 0.009) (3)DCR: TACE + sunitinib group, 85.1%; sunitinib group, 66.7%. (P = 0.038) (4) In the TACE + sunitinib group, mPFS was 15.6 months, mOS was 35.0 months; in the sunitinib group, the mPFS was 10.9 months, mOS was 25.7 months. (P < 0.001) (5) The incidence of abdominal pain, fever, and vomiting was higher in the TACE + sunitinib group than in the sunitinib group (abdominal pain: 55.3% vs. 13.7%; fever: 61.7% vs. 7.8%; vomiting: 40.4% vs. 19.6%; P < 0.05). The technical success rate of TACE in TACE + Sunitinib group is 100%.

Conclusions

The TACE + sunitinib group had higher ORR and DCR, longer OS and PFS than the sunitinib alone group. TACE combined with sunitinib can play a complementary role and is a safe and effective treatment for advanced RCC.

Randall JM, Millard F, Kurzrock R. Molecular aberrations, targeted therapy, and renal cell carcinoma: current state-of-the-art. Cancer Metastasis Rev. 2014 Dec;33(4):1109-24. doi: https://doi.org/10.1007/s10555-014-9533-1. PMID: 25365943.

Spadaccino F, Netti GS, Rocchetti MT, Castellano G, Stallone G, Ranieri E. [Diagnostic and prognostic markers of renal cell carcinoma]. G Ital Nefrol. 2020 Apr 9;37(2):2020-vol2. Italian. PMID: 32281759.

Pullen RL Jr. Renal cell carcinoma, part 1. Nursing. 2021 Jul 1;51(7):34–40. doi: https://doi.org/10.1097/01.NURSE.0000753972.19135.dc. PMID: 34156999.

Huang J, Leung DK, Chan EO, Lok V, Leung S, Wong I, Lao XQ, Zheng ZJ, Chiu PK, Ng CF, Wong JH, Volpe A, Merseburger AS, Powles T, Teoh JY, Wong MCS. A Global Trend analysis of kidney Cancer incidence and mortality and their Associations with Smoking, Alcohol Consumption, and metabolic syndrome. Eur Urol Focus. 2022 Jan;8(1):200–9. Epub 2021 Jan 23. PMID: 33495133.

Linehan WM, Ricketts CJ. The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol. 2019 Sep;16(9):539–552. doi: https://doi.org/10.1038/s41585-019-0211-5. Epub 2019 Jul 5. PMID: 31278395.

Mendhiratta N, Muraki P, Sisk AE Jr, Shuch B. Papillary renal cell carcinoma: review. Urol Oncol. 2021 Jun;39(6):327–37. https://doi.org/10.1016/j.urolonc.2021.04.013. Epub 2021 May 24. PMID: 34034966.

Garje R, Elhag D, Yasin HA, Acharya L, Vaena D, Dahmoush L. Comprehensive review of chromophobe renal cell carcinoma. Crit Rev Oncol Hematol. 2021 Apr;160:103287. https://doi.org/10.1016/j.critrevonc.2021.103287. Epub 2021 Mar 19. PMID: 33753250.

Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Kuusk T, Lam TB, Marconi L, Merseburger AS, Powles T, Staehler M, Tahbaz R, Volpe A, Bex A. European Association of Urology Guidelines on Renal Cell Carcinoma: the 2019 Update. Eur Urol. 2019 May;75(5):799–810. Epub 2019 Feb 23. PMID: 30803729.

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Grünwald V, Gillessen S, Horwich A, ESMO Guidelines Committee. ;. Electronic address: clinicalguidelines@esmo.org. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. Ann Oncol. 2019 May 1;30(5):706–720. doi: https://doi.org/10.1093/annonc/mdz056. PMID: 30788497.

10.

Liu Z, Li Y, Zhao X, Ge L, Zhu G, Hong P, Tang S, Zhang S, Tian X, Wang S, Liu C, Zhang H, Ma L. Renal cell carcinoma with tumor thrombus growing against the direction of venous return: an indicator of complicated surgery and poor prognosis. BMC Surg. 2021 Dec 28;21(1):443. doi: https://doi.org/10.1186/s12893-021-01448-0. PMID: 34963464; PMCID: PMC8713414.

11.

Chen Z, Yang F, Ge L, Qiu M, Liu Z, Liu C, Tian X, Zhang S, Ma L. Outcomes of renal cell carcinoma with associated venous tumor thrombus: experience from a large cohort and short time span in a single center. BMC Cancer. 2021 Jul 2;21(1):766. doi: https://doi.org/10.1186/s12885-021-08508-x. PMID: 34215223; PMCID: PMC8254310.

12.

Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, Gruenvald V, Horwich A, ESMO Guidelines Committee. ;. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(suppl 5):v58-v68. doi: https://doi.org/10.1093/annonc/mdw328. Erratum in: Ann Oncol. 2017 Jul 1;28(suppl_4):iv167-iv168. PMID: 27664262.

13.

Quhal F, Mori K, Bruchbacher A, Resch I, Mostafaei H, Pradere B, Schuettfort VM, Laukhtina E, Egawa S, Fajkovic H, Remzi M, Shariat SF, Schmidinger M. First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.Eur Urol Oncol. 2021Oct;4(5):755–765. doi: 10.1016/j.euo.2021.03.001. Epub 2021 Mar 20. PMID: 33757737.

14.

Motzer RJ, Escudier B, McDermott DF, Arén Frontera O, Melichar B, Powles T, Donskov F, Plimack ER, Barthélémy P, Hammers HJ, George S, Grünwald V, Porta C, Neiman V, Ravaud A, Choueiri TK, Rini BI, Salman P, Kollmannsberger CK, Tykodi SS, Grimm MO, Gurney H, Leibowitz-Amit R, Geertsen PF, Amin A, Tomita Y, McHenry MB, Saggi SS, Tannir NM. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. J Immunother Cancer. 2020 Jul;8(2):e000891. doi: https://doi.org/10.1136/jitc-2020-000891. Erratum in: J Immunother Cancer. 2021 May;9(5): PMID: 32661118; PMCID: PMC7359377.

15.

Singla N, Hutchinson RC, Ghandour RA, Freifeld Y, Fang D, Sagalowsky AI, Lotan Y, Bagrodia A, Margulis V, Hammers HJ, Woldu SL. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: an analysis of the National Cancer Database. Urol Oncol. 2020 Jun;38(6):604. .e9-604.e17. Epub 2020 Apr 3. PMID: 32253116; PMCID: PMC7269798.

16.

Yamada R, Bassaco B, Bracewell S, Gillen K, Kocher M, Collins H, Anderson MB, Guimaraes M. Long-term follow-up after conventional transarterial chemoembolization (c-TACE) with mitomycin for hepatocellular carcinoma (HCC). J Gastrointest Oncol. 2019 Apr;10(2):348–53. https://doi.org/10.21037/jgo.2019.01.01. PMID: 31032104; PMCID: PMC6465494.

17.

Gunn AJ, Patel AR, Rais-Bahrami S. Role of Angio-Embolization for Renal Cell Carcinoma. Curr Urol Rep. 2018 Aug 8;19(10):76. doi: https://doi.org/10.1007/s11934-018-0827-7. PMID: 30091047.

18.

Sakr OS, Berndt S, Carpentier G, Cuendet M, Jordan O, Borchard G. Arming embolic beads with anti-VEGF antibodies and controlling their release using LbL technology. J Control Release. 2016 Feb 28;224:199–207. doi: https://doi.org/10.1016/j.jconrel.2016.01.010. Epub 2016 Jan 11. PMID: 26780173.

19.

Zhou M, Zhang C, Nie J, Sun Y, Xu Y, Wu F, Huang Y, Li S, Wang Y, Zhou Y, Zheng T. Response Evaluation and Survival Prediction Following PD-1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria.Front Oncol. 2021 Dec9;11:764189. doi: https://doi.org/10.3389/fonc.2021.764189. PMID: 34956885; PMCID: PMC8697350.

20.

Wiechno P, Kucharz J, Sadowska M, Michalski W, Sikora-Kupis B, Jonska-Gmyrek J, Poniatowska G, Nietupski K, Ossolinski K, Demkow T. Contemporary treatment of metastatic renal cell carcinoma. Med Oncol. 2018 Oct 27;35(12):156. doi: https://doi.org/10.1007/s12032-018-1217-1. PMID: 30368624.

21.

Hahn AW, Klaassen Z, Agarwal N, Haaland B, Esther J, Ye XY, Wang X, Pal SK, Wallis CJD. First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. Eur Urol Oncol. 2019 Nov;2(6):708–715. doi: 10.1016/j.euo.2019.09.002. Epub 2019 Oct 4. PMID: 31588018.

22.

McDermott DF, Atkins MB. Application of IL-2 and other cytokines in renal cancer. Expert Opin Biol Ther. 2004 Apr;4(4):455 – 68. doi: https://doi.org/10.1517/14712598.4.4.455. PMID: 15102596.

23.

de Velasco G, Hamieh L, Mickey S, Choueiri TK. Optimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting. Urol Oncol. 2015 Dec;33(12):538–45. https://doi.org/10.1016/j.urolonc.2015.08.007. Epub 2015 Oct 9. PMID: 26482392; PMCID: PMC4654640.

24.

Choueiri TK, Motzer RJ. Systemic Therapy for Metastatic Renal-Cell Carcinoma. N Engl J Med. 2017 Jan 26;376(4):354–366. doi: https://doi.org/10.1056/NEJMra1601333. PMID: 28121507.

25.

Gluskin J, Plodkowski A, Girshman J, Sarasohn D, Viteri-Jusué A, Hayan S, Torrisi J. Waxing and waning pattern of mTOR inhibitor-associated pneumonitis in renal cell carcinoma patients: a retrospective observational study. Clin Imaging. 2021 Mar;71:29–33. https://doi.org/10.1016/j.clinimag.2020.10.052. Epub 2020 Nov 5. PMID: 33171363; PMCID: PMC7855089.

26.

McDermott DF, George DJ. Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data. Cancer Treat Rev. 2010 May;36(3):216–23. https://doi.org/10.1016/j.ctrv.2009.12.003. Epub 2010 Jan 29. PMID: 20116176.

27.

Roskoski R Jr. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.Pharmacol Res. 2017 Jun;120:116–132. doi: https://doi.org/10.1016/j.phrs.2017.03.010. Epub 2017 Mar 19. PMID: 28330784.

28.

Badran A, Elshenawy MA, Shahin A, Aljubran A, Alzahrani A, Eldali A, Bazarbashi S. Efficacy and Prognostic Factors of Sunitinib as First-Line Therapy for Patients With Metastatic Renal Cell Carcinoma in an Arab Population.JCO Glob Oncol. 2020 Feb;6:19–26. doi: 10.1200/JGO.19.00111. PMID: 32031432; PMCID: PMC6998020.

29.

Moran M, Nickens D, Adcock K, Bennetts M, Desscan A, Charnley N, Fife K. Target Oncol. 2019 Aug;14(4):405–16. PMID: 31301015; PMCID: PMC6684538. Sunitinib for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World and Clinical Trials Data.

30.

Liu XL, Xue HY, Chu Q, Liu JY, Li J. Comparative efficacy and safety of sunitinib vs sorafenib in renal cell carcinoma: A systematic review and meta-analysis. Medicine (Baltimore). 2020 Mar;99(13):e19570. doi: https://doi.org/10.1097/MD.0000000000019570. PMID: 32221075; PMCID: PMC7220148.

31.

Ramaswamy RS, Darcy MD. Arterial Embolization for the Treatment of Renal Masses and Traumatic Renal Injuries. Tech Vasc Interv Radiol. 2016 Sep;19(3):203 – 10. doi: https://doi.org/10.1053/j.tvir.2016.06.005. Epub 2016 Jun 3. PMID: 27641454.

32.

Wright B, Johnson BS, Vassar M, Saidian A, Rais-Bahrami S, Gunn AJ. Trans-arterial embolization of renal cell carcinoma: a systematic review and meta-analysis. Abdom Radiol (NY). 2022 Apr 5. doi: https://doi.org/10.1007/s00261-022-03502-8. Epub ahead of print. PMID: 35380246.

33.

Duan XH, Li YS, Han XW, Wang YL, Jiao DC, Li TF, Chen PF, Fang Y. C-arm CT-guided renal arterial embolisation followed by radiofrequency ablation for treatment of patients with unresectable renal cell carcinoma. Clin Radiol. 2016 Jan;71(1):79–85. Epub 2015 Nov 18. PMID: 26602936.

34.

Wallace S, Charnsangavej C, Carrasco CH, Bechtel W, Infusion-embolization. Cancer. 1984 Dec 1;54(11 Suppl):2751-65. doi: https://doi.org/10.1002/1097-0142(19841201)54:2+>2751::aid-cncr2820541423<3.0.co;2-5. PMID: 6093984.

35.

Ramaswamy RS, Akinwande O, Tiwari T. Renal Embolization: Current Recommendations and Rationale for Clinical Practice. Curr Urol Rep. 2018 Feb 5;19(3):5. doi: https://doi.org/10.1007/s11934-018-0756-5. PMID: 29399726.

36.

Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J. A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802. Med Oncol. 2012 Jun;29(2):761–7. https://doi.org/10.1007/s12032-011-9829-8. Epub 2011 Feb 6. PMID: 21298497; PMCID: PMC3566570.

37.

Acharya N, Singh KP. Differential sensitivity of renal carcinoma cells to doxorubicin and epigenetic therapeutics depends on the genetic background. Mol Cell Biochem. 2021 Jun;476(6):2365–79. https://doi.org/10.1007/s11010-021-04076-7. Epub 2021 Feb 16. PMID: 33591455.

38.

Park JH, Kim SH, Han JK, Chung JW, Han MC. Transcatheter arterial embolization of unresectable renal cell carcinoma with a mixture of ethanol and iodized oil. Cardiovasc Intervent Radiol. 1994 Nov-Dec;17(6):323-7. doi: https://doi.org/10.1007/BF00203951. PMID: 7533666.

39.

Perdana NR, Daulay ER, Prapiska FF. Renal Arteries Embolization in Unresectable Clear Cell Renal Carcinoma: First Time Experience at Haji Adam Malik Hospital. Open Access Maced J Med Sci. 2018 Aug 19;6(8):1454–1457. doi: https://doi.org/10.3889/oamjms.2018.282. PMID: 30159076; PMCID: PMC6108812.

40.

Kato T, Nemoto R, Mori H, Takahashi M, Tamakawa Y. Transcatheter arterial chemoembolization of renal cell carcinoma with microencapsulated mitomycin C. J Urol. 1981 Jan;125(1):19–24. doi: https://doi.org/10.1016/s0022-5347(17)54880-6. PMID: 7463576.

41.

Saitoh H, Hayakawa K, Nishimura K, Kubo S, Hida S. Long-term results of ethanol embolization of renal cell carcinoma. Radiat Med. 1997 Mar-Apr;15(2):99–102. PMID: 9192434.

42.

Granov AM, Gorelov AI, Gershanovich ML, Karelin MI, Vorob’ev AV, Filov VA, Stukov AN. Resul’taty primeneniia éndovaskuliarnykh vmeshatel’stv (émbolizatsii i khimioèmbolizatsii) v lechenii operabel’nogo i rasprostranennogo raka pochki [Results of endovascular interventions (embolization and chemoembolization) in the treatment of operable and extensive kidney cancer]. Vopr Onkol. 1998;44(6):711–4. Russian. PMID: 10087971.PubMed

43.

Liu K, Min XL, Peng J, Yang K, Yang L, Zhang XM. The changes of HIF-1α and VEGF expression after TACE in patients with Hepatocellular Carcinoma. J Clin Med Res. 2016 Apr;8(4):297–302. https://doi.org/10.14740/jocmr2496w. Epub 2016 Feb 27. PMID: 26985249; PMCID: PMC4780492.

44.

Daniela S, Krause,Richard A, Van Etten. Tyrosine kinases as targets for cancer therapy. N Engl J Med. 2005;353(2):172–87. https://doi.org/10.1056/NEJMra044389.CrossRef

45.

Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol. 2006 Aug;33(4):392–406. doi: https://doi.org/10.1053/j.seminoncol.2006.04.002. PMID: 16890795.

46.

Deng J, Wen F. Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors for Intermediate-Stage Hepatocellular Carcinoma, What Else Can We Do? Front Oncol. 2022 Mar 29;12:824799. doi: https://doi.org/10.3389/fonc.2022.824799. PMID: 35425716; PMCID: PMC9001928.

47.

Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y. ; TACTICS study group. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.Gut. 2020Aug;69(8):1492–1501. doi: https://doi.org/10.1136/gutjnl-2019-318934. Epub 2019 Dec 4. PMID: 31801872; PMCID: PMC7398460.

48.

Fu Z, Li X, Zhong J, Chen X, Cao K, Ding N, Liu L, Zhang X, Zhai J, Qu Z. Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study.Hepatol Int. 2021Jun;15(3):663–675. doi: https://doi.org/10.1007/s12072-021-10184-9. Epub 2021 Apr 20. PMID: 33877527; PMCID: PMC8286947.

49.

Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B, Rainbow Group. ;. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol. 2016 Feb;27(2):366. doi: https://doi.org/10.1093/annonc/mdv589. Epub 2015 Dec 18. Erratum for: Ann Oncol. 2015 Oct;26(10):2107-13. PMID: 26685011.

50.

Onishi T, Oishi Y, Suzuki Y, Asano K. Prognostic evaluation of transcatheter arterial embolization for unresectable renal cell carcinoma with distant metastasis. BJU Int. 2001 Mar;87(4):312-5. doi: https://doi.org/10.1046/j.1464-410x.2001.00070.x. PMID: 11251521.

51.

Bi Y, Shi X, Ren J, Yi M, Han X. Transarterial chemoembolization of unresectable renal cell carcinoma with doxorubicin-loaded CalliSpheres drug-eluting beads. Sci Rep. 2022 May 17;12(1):8136. doi: https://doi.org/10.1038/s41598-022-12334-x. PMID: 35581365; PMCID: PMC9113996.

52.

Qin SK, Jin J, Guo J, Wang JW, Zhou FJ, Huang YR, Ren XB, Ye DW, Pan S, Sajben P, Wang Q. Efficacy and safety of first-line sunitinib in chinese patients with metastatic renal cell carcinoma. Future Oncol. 2018 Aug;14(18):1835–45. https://doi.org/10.2217/fon-2017-0733. Epub 2018 May 2. PMID: 29717651.

Title: Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study
Authors: Haohao Lu, MD
Qing Ye, MD
Chuansheng Zheng, MD,PhD
Li Fan, MD,PhD
Xiangwen Xia, MD,PhD
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Kidney Cancer
Kidney Cancer
Kidney Cancer
Sunitinib
Published in: BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-023-10754-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Determinants of late-stage cervical cancer presentation in Ethiopia: a systematic review and meta-analysis

Effects of neoadjuvant radiochemotherapy for anorectal function in locally advanced rectal cancer patients: a study protocol for a prospective, observational, controlled, multicentre study

Predicting survival for patients with mesothelioma: development of the PLACE prognostic model

Hsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center

The combination of PD-L1 expression and the neutrophil-to-lymphocyte ratio as a prognostic factor of postoperative recurrence in non-small-cell lung cancer: a retrospective cohort study

Personalized surveillance and aftercare for non-metastasized breast cancer: the NABOR study protocol of a multiple interrupted time series design

Keynote webinar | Spotlight on antibody–drug conjugates in cancer